Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals for ADPKD Development
• Kyoto-based Rege Nephro has acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals to advance its ADPKD treatment program.
• Tamibarotene (RN-014), a retinoic acid receptor agonist, is currently in Phase 2 trials in Japan for ADPKD with plans to expand clinical development to the United States.
• The acquisition includes human safety data for NDA submission, manufacturing contracts, and drug products, potentially accelerating Rege Nephro's U.S. clinical development timeline.
Rege Nephro Secures $150 Million in Series B Funding to Advance Kidney Disease Therapies
• Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies.
• The funding will support Phase II trials of RN-014, a retinoic acid receptor agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and preparations for US trials.
• Funds will also facilitate preclinical trials for RN-032, a cell therapy targeting Chronic Kidney Disease (CKD) using nephron progenitor cells.
• The investment underscores confidence in Rege Nephro's iPSC-based technology and its potential to address unmet needs in kidney disease treatment.
© Copyright 2025. All Rights Reserved by MedPath